We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-17.92%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$999M
AUM Growth
-$111M
Cap. Flow
+$145M
Cap. Flow %
14.51%
Top 10 Hldgs %
53.54%
Holding
68
New
18
Increased
13
Reduced
17
Closed
15
Avg Time Held Equity + Options
2.6 quarters
Top 10 Avg Time Held Equity + Options
5 quarters
Top 20 Avg Time Held Equity + Options
3.5 quarters
Avg Time Held Equity only
2.6 quarters
Top 10 Avg Time Held Equity only
5.4 quarters
Top 20 Avg Time Held Equity only
3.6 quarters

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$73.3M
2
XNCR icon
Xencor
XNCR
+$36.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$33.3M
4
SLDB icon
Solid Biosciences
SLDB
+$27.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$25.8M

Top Sells

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$31.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$25.6M
3
KYNB icon
Kyntra Bio
KYNB
+$22.2M
4
SRRK icon
Scholar Rock
SRRK
+$20.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.99%
2 Miscellaneous 13.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARGX icon
1
argenx
ARGX
$50.5B
$79.3M 7.93%
+825,087
New +$73.3M
2018 Q4
0 quarters
KURA icon
2
Kura Oncology
KURA
$874M
$74.1M 7.41%
5,276,753
+1,373,778
+35% +$18.2M
2015 Q4
12 quarters
KYNB icon
3
Kyntra Bio
KYNB
$23.8M
$70.6M 7.06%
60,982
-19,708
-24% -$22.2M
2014 Q4
16 quarters
IRWD icon
4
Ironwood Pharmaceuticals
IRWD
$593M
$55.8M 5.58%
6,425,251
+286,152
+5% +$3.28M
2015 Q4
12 quarters
ASMB icon
5
Assembly Biosciences
ASMB
$414M
$54.4M 5.44%
200,404
-44,860
-18% -$13M
2014 Q4
16 quarters
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$44.5M 4.45%
1,136,851
+299,803
+36% +$13M
2018 Q3
1 quarter
ASND icon
7
Ascendis Pharma A/S
ASND
$14.7B
$42.6M 4.26%
679,746
-407,511
-37% -$25.6M
2016 Q3
9 quarters
IONS icon
8
Ionis Pharmaceuticals
IONS
$7.04B
$39.2M 3.92%
725,326
+653,000
+903% +$33.3M
2018 Q3
1 quarter
KYNB icon
9
CALL
Kyntra Bio
KYNB
$23.8M
$38.9M 3.89%
33,632
+19,632
+140% +$22.1M
2017 Q4
4 quarters
XNCR icon
10
Xencor
XNCR
$1.75B
$35.8M 3.58%
+989,018
New +$36.3M
2018 Q4
0 quarters
DRNA
11
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$35.5M 3.55%
3,316,407
-485,920
-13% -$6.39M
2017 Q1
7 quarters
SRRK icon
12
Scholar Rock
SRRK
$4.93B
$33.9M 3.39%
1,474,228
-893,150
-38% -$20.2M
2018 Q2
2 quarters
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$27.5M 2.75%
+647,169
New +$25.8M
2018 Q4
0 quarters
KZR icon
14
DELISTED
Kezar Life Sciences
KZR
$25M 2.5%
106,002
-22,818
-18% -$5.58M
2018 Q2
2 quarters
SLDB icon
15
Solid Biosciences
SLDB
$624M
$23.2M 2.33%
+57,816
New +$27.2M
2018 Q4
0 quarters
ASND icon
16
PUT
Ascendis Pharma A/S
ASND
$14.7B
$22.6M 2.26%
+360,000
New +$22.6M
2018 Q4
0 quarters
AKCA
17
DELISTED
Akcea Therapeutics Inc
AKCA
$19.3M 1.93%
639,743
-115,377
-15% -$3.23M
2018 Q3
1 quarter
GILD icon
18
CALL
Gilead Sciences
GILD
$183B
$17.8M 1.78%
285,100
-7,500
-3% -$524K
2018 Q2
2 quarters
EIGR
19
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$16.2M 1.62%
53,188
+18,538
+54% +$5.99M
2018 Q2
2 quarters
UBX icon
20
DELISTED
Unity Biotechnology
UBX
$15.7M 1.57%
96,711
– –
2018 Q2
2 quarters
ASND icon
21
CALL
Ascendis Pharma A/S
ASND
$14.7B
$15.7M 1.57%
250,400
-6,600
-3% -$415K
2018 Q2
2 quarters
SGMO icon
22
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$13.6M 1.36%
1,185,831
+842,600
+245% +$10.5M
2018 Q2
2 quarters
ZLAB icon
23
Zai Lab
ZLAB
$2.59B
$13.2M 1.32%
569,377
+219,377
+63% +$4.07M
2018 Q3
1 quarter
RCUS icon
24
Arcus Biosciences
RCUS
$2.87B
$13.2M 1.32%
1,223,495
-1,012,892
-45% -$11.8M
2018 Q1
3 quarters
ABUS icon
25
Arbutus Biopharma
ABUS
$814M
$12.6M 1.26%
3,281,502
+2,049,702
+166% +$10.1M
2018 Q3
1 quarter
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2018 Portfolio in Review

As of Q4 2018, EcoR1 Capital held 68 positions worth $999M, down 10% from $1.11B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

EcoR1 Capital deployed $145M of net new capital in Q4 2018, opening 18 new positions and adding to 13 existing holdings. Its largest new stake was argenx: 825,087 shares worth $79.3M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 87% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $25.6M trimmed.

  • EcoR1 Capital's largest Q4 2018 buy was argenx: 825,087 shares worth $79.3M.
  • EcoR1 Capital added most to Ionis Pharmaceuticals in Q4 2018, an estimated $33.3M increase.
  • EcoR1 Capital's biggest Q4 2018 reduction was Ascendis Pharma A/S, cutting an estimated $25.6M.
  • EcoR1 Capital fully exited MacroGenics in Q4 2018, selling an estimated $31.8M.
  • EcoR1 Capital's ten largest holdings make up 54% of its $999M portfolio in Q4 2018.
  • EcoR1 Capital opened 18 new positions and closed 15 in Q4 2018.
  • EcoR1 Capital's portfolio value fell 10% quarter-over-quarter to $999M.

Based on EcoR1 Capital's 13F filing for Q4 2018, filed 14 Feb 2019.